市場調査レポート

商品コード

1722285

オンコロジー分子診断薬の市場規模、シェア、成長分析、タイプ別、製品別、技術別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Oncology Molecular Diagnostics Market Size, Share, and Growth Analysis, By Type (Breast Cancer, Prostate Cancer), By Product, By Technology, By End User, By Region, And Segment Forecast, 2025-2032

出版日: 2025年05月02日
発行: SkyQuest
ページ情報: 英文 187 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 775,496円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 907,184円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,038,872円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.32円

全表示
概要
目次

概要

サンプル依頼リストに入れる

オンコロジー分子診断薬の世界市場規模は2023年に24億7,000万米ドルと評価され、予測期間（2025-2032年）のCAGRは11.6%で、2024年の25億7,000万米ドルから2032年には57億8,000万米ドルに成長する見通しです。

オンコロジー分子診断薬市場は、個別化医療に対する需要の高まりと世界のがん罹患率の上昇を背景に急成長を遂げています。これらの診断薬は、早期の腫瘍プロファイリングや治療選択において重要な役割を果たしており、がん専門医はがんの進行や治療効果に影響を与える遺伝子変異やバイオマーカーを特定することができます。次世代シーケンシング、ポリメラーゼ連鎖反応、in situハイブリダイゼーションの技術的進歩は、これらの能力を高めています。さらに、精密腫瘍学へのシフトは、より深い腫瘍生物学的洞察に基づいて標的治療が増殖するにつれて、コンパニオン診断薬の必要性を強調しています。しかし、特に中低所得国では、高い検査費用とアクセスの障壁が課題となっています。技術革新、支援的な医療政策、協力関係の重視に加え、診断へのAIの導入が進むことで、市場環境はさらに強化されると予想されます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Abbott Laboratories（United States）
F. Hoffmann-La Roche Ltd（Switzerland）
Thermo Fisher Scientific Inc.（United States）
Danaher Corporation（United States）
Veracyte Inc.（United States）
Sysmex Corporation（Japan）
Illumina, Inc.（United States）
bioMerieux SA（France）
Agilent Technologies Inc.（United States）
TBG Diagnostics Limited（Australia）
HTG Molecular Diagnostics Inc.（United States）
QIAGEN（Netherlands）
NeoGenomics Laboratories, Inc.（United States）
Foundation Medicine, Inc.（United States）
Natera, Inc.（United States）
Myriad Genetics, Inc.（United States）
Guardant Health（United States）
Exact Sciences Corporation（United States）
Tempus AI（United States）
Flatiron Health（United States）

結論と提言

Product Code: SQMIG35A3002

Global Oncology Molecular Diagnostics Market size was valued at USD 2.47 Billion in 2023 and is poised to grow from USD 2.57 Billion in 2024 to USD 5.78 Billion by 2032, growing at a CAGR of 11.6% during the forecast period (2025-2032).

The oncology molecular diagnostics market is experiencing rapid growth driven by the rising demand for personalized medicine and escalating global cancer prevalence. These diagnostics play a crucial role in early tumor profiling and treatment selection, enabling oncologists to pinpoint genetic mutations and biomarkers that influence cancer progression and therapy response. Technological advancements in next-generation sequencing, polymerase chain reaction, and in situ hybridization enhance these capabilities. Additionally, the shift towards precision oncology emphasizes the need for companion diagnostics, as targeted therapies proliferate based on deeper tumor biology insights. However, high test costs and access barriers, particularly in low- and middle-income countries, pose challenges. An emphasis on innovation, supportive health policies, and collaborations, alongside the growing incorporation of AI in diagnostics, is expected to further strengthen the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Oncology Molecular Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Oncology Molecular Diagnostics Market Segments Analysis

The global Oncology Molecular Diagnostics Market is segmented on the basis of type, product, technology, and region. By type, the market is segmented into breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, kidney cancer, and other cancer. By product, the market is segmented into instruments, reagents and others. By technology, the market is segmented into PCR, In situ hybridization, INAAT, chips and microarrays, mass spectrometry, sequencing, TMA, and others. By end User, the market segmented into hospitals, diagnostic laboratories, academic & research institutes, and others. By region, the market is segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.

Driver of the Global Oncology Molecular Diagnostics Market

The global oncology molecular diagnostics market is primarily driven by the rising incidence of cancer across the globe. As the prevalence of cancer continues to escalate, the demand for precise and swift diagnostic methods becomes increasingly vital for improving survival rates. Molecular diagnostics play a crucial role by analyzing cancer at the genetic level, helping to confirm early diagnoses, identify targeted therapies, and facilitate more accurate monitoring of disease progression. This approach not only enhances patient outcomes but also contributes to reducing overall treatment costs, making it a significant factor influencing the growth of the oncology molecular diagnostics market.

Restraints in the Global Oncology Molecular Diagnostics Market

The Global Oncology Molecular Diagnostics market faces several constraints, primarily due to the high costs associated with molecular diagnostic tests, such as next-generation sequencing (NGS) and companion diagnostics. These tests necessitate sophisticated and costly equipment, specialized expertise, and well-organized laboratory environments, which render them financially inaccessible for numerous patients, particularly in low- and middle-income nations. Additionally, stringent reimbursement policies and elevated out-of-pocket expenses further exacerbate challenges in accessing timely care, hindering prompt diagnosis and treatment of cancer. Collectively, these factors are expected to limit the growth of the market significantly.

Market Trends of the Global Oncology Molecular Diagnostics Market

The Global Oncology Molecular Diagnostics market is witnessing a transformative shift driven by technological advancements, particularly in next-generation sequencing (NGS) and liquid biopsy innovations. These methods facilitate faster, non-invasive cancer detection and monitoring, offering enhanced sensitivity and broader genomic coverage essential for both clinical applications and research initiatives. As healthcare providers increasingly adopt these advanced solutions, the demand for accurate and timely diagnostic tools continues to grow. This trend signifies a pivotal move towards personalized medicine, empowering clinicians with vital data to tailor therapies, ultimately improving patient outcomes and fueling market expansion in the oncology diagnostics landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Matrix
Regulation Matrix

Global Oncology Molecular Diagnostics Market Size by Type & CAGR (2025-2032)

Market Overview
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Other Cancer

Global Oncology Molecular Diagnostics Market Size by Product & CAGR (2025-2032)

Market Overview
Instruments
Reagents
Others

Global Oncology Molecular Diagnostics Market Size by Technology & CAGR (2025-2032)

Market Overview
PCR
In Situ Hybridization
INAAT
Chips and Microarrays
Mass Spectrometry
Sequencing
TMA
Others

Global Oncology Molecular Diagnostics Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Diagnostic Laboratories
Academic & Research Institutes
Others

Global Oncology Molecular Diagnostics Market Size & CAGR (2025-2032)

North America (Type, Product, Technology, End User)
- US
- Canada
Europe (Type, Product, Technology, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Product, Technology, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Product, Technology, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Product, Technology, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Abbott Laboratories (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Veracyte Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TBG Diagnostics Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
HTG Molecular Diagnostics Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics Laboratories, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tempus AI (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Flatiron Health (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

オンコロジー分子診断薬の市場規模、シェア、成長分析、タイプ別、製品別、技術別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Oncology Molecular Diagnostics Market Size, Share, and Growth Analysis, By Type (Breast Cancer, Prostate Cancer), By Product, By Technology, By End User, By Region, And Segment Forecast, 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

オンコロジー分子診断薬市場規模：タイプ別& CAGR（2025-2032）

オンコロジー分子診断薬市場規模：製品別& CAGR（2025-2032）

オンコロジー分子診断薬市場規模：技術別& CAGR（2025-2032）

オンコロジー分子診断薬市場規模：エンドユーザー別& CAGR（2025-2032）

オンコロジー分子診断薬市場規模：地域別& CAGR（2025-2032）